PRPF18

Across TCGA pan-cancer cohorts, PRPF18 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PRPF18 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher PRPF18 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PRPF18 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, HNSC, and LUAD are the cancer types where PRPF18 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	All	0.915	0.728	.007	13	view →
HNSC	DFS	Quartile	III,IV	0.634	0.879	.037	13	view →
LUAD	DFS	Median	All	0.844	0.425	.005	12	view →
PDAC	DFS	Tertile	III,IV	0.789	0.376	.024	9	view →
CCRCC	OS	Quartile	All	0.912	1.000	.040	4	view →
UCEC	OS	Quartile	II,III,IV	1.000	0.437	.025	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRPF18–LSCC (OS)

Open the LSCC breakdown →